To differentiate subtypes of microglia (MG), we developed a novel monoclonal antibody, 9F5, against one subtype (type 1) of rat primary MG. The 9F5 showed high selectivity for this cell type in Western blot and immunocytochemical analyses and no cross-reaction with rat peritoneal macrophages (Mu). We identified the antigen molecule for 9F5: the 50-to 70-kDa fragments of rat glycoprotein nonmetastatic melanoma protein B (GPNMB)/osteoactivin, which started at Lys 170 . In addition, 9F5 immunoreactivity with GPNMB depended on the activity of furin-like protease(s). More important, rat type 1 MG expressed the GPNMB fragments, but type 2 MG and Mu did not, although all these cells expressed mRNA and the full-length protein for GPNMB. These results suggest that 9F5 reactivity with MG depends greatly on cleavage of GPNMB and that type 1 MG, in contrast to type 2 MG and Mu, may have furin-like protease(s) for GPNMB cleavage. In neonatal rat brain, amoeboid 9F51 MG were observed in specific brain areas including forebrain subventricular zone, corpus callosum, and retina. Doubleimmunostaining with 9F5 antibody and anti-Iba1 antibody, which reacts with MG throughout the CNS, revealed that 9F51 MG were a portion of Iba11 MG, suggesting that MG subtype(s) exist in vivo. We propose that 9F5 is a useful tool to discriminate between rat type 1 MG and other subtypes of MG/Mu and to reveal the role of the GPNMB fragments during developing brain.
Introduction
M icroglia (MG) are immune cells in the CNS and can protect it against infection and injuries via phagocytosis, antigen presentation, and cytokine secretion (Kreutzberg, 1996) . During development, MG invade CNS tissue at very early stages, before or simultaneously with neurogenesis (Dalmau et al., 1997) . Evidence now suggests that MG at such developmental stages may be associated with the need to phagocytose debris and apoptotic neurons after brain development and to deliver growth factors and cytokines to support cell proliferation and neuronal organization (Bessis et al., 2007; Cuadros and Navascues, 1998; Hanisch, 2002; Streit, 2001) . MG are also involved in synaptic pruning in developing mouse brain (Paolicelli et al., 2011; Stevens et al., 2007) .
Recent reports suggest that two or more subtypes of MG may exist in the CNS. Andjelkovic et al. (1998) suggested that MG have a dual origin, the first being yolk-sac macrophages (Mu) during the nonvascularized prenatal stage, followed by the second, as circulating monocytes engraft in the postnatal brain. Independent studies have also suggested this hypothesis (for review, see Chan et al., 2007) , and fatemapping analysis revealed that almost all MG in adult brain derive from yolk-sac Mu (Ginhoux et al., 2010) . Apart from arguments about the origins of MG, several additional papers reported on MG heterogeneity. In the absence of pathological situations, human MG that are positive for MHC class II and CD4 are preferentially found in white matter, rather than gray matter, brain regions (Hayes et al., 1987) . Rat hippocampal MG express higher levels of mRNAs for tumor necrosis factor-a, CD4, and Fcc receptor type II (CD32) than do MG from the diencephalon, tegmentum, cerebellum, and cerebral cortex (Ren et al., 1999) . Bulloch et al. (2008) showed that CD11c1 dendritic cells reside among the heterogeneous MG population in normal mouse brain. These results strongly suggest that heterogeneity of MG subtypes exists in the CNS.
We previously demonstrated that interleukin (IL)24-stimulated uptake and degradation of b-amyloid peptide were selectively enhanced in one MG subtype, i.e., type 2 MG, but not in type 1 MG that express CD40 (Shimizu et al., 2008) . We also showed a marked induction of inducible nitric oxide synthase and tumor necrosis factor-a in type 1 MG compared with type 2 MG under inflammatory conditions (Kawahara et al., 2009 ). These results suggest that these two MG subtypes may play different neuroimmunomodulatory roles in diseased brains. However, the lineages and functions of these subtypes in the brain remain largely unknown. The lack of specific tools to differentiate such subtypes is a key issue for these investigations. In addition, the characterization of MG is even more difficult than that of neurons and other glial cells because MG share several antigens with peripheral Mu (e.g., CD11b, CD68, Iba1, and others). Therefore, developing tools to differentiate MG and Mu accurately and easily is necessary.
Here, we report the development of a novel monoclonal antibody, 9F5, which not only showed no cross-reactivity with peritoneal Mu but also recognized a fraction of the total MG population. We also determined that the antigen protein for 9F5 consists of fragments of rat transmembrane glycoprotein nonmetastatic melanoma protein B(GPNMB)/osteoactivin processed by furin-like protease(s). Type 1 MG but neither type 2 MG nor Mu expressed the antigen molecule for 9F5. By using 9F5 antibody, we demonstrated the existence of truncated GPNMB1 MG in vivo.
Materials and Methods

Animals
Wistar rats and BALB/c mice were obtained from Kyudo and Japan SLC, respectively. Gpnmb mutant mice [Gpnmbtm1(Gfp)Mcf ] were generated as described in Supporting Information. The day after overnight mating was considered embryonic day 0 (E0), and the day of birth was designated postnatal day 0 (P0). Animals were treated according to the Guidelines of the Institutional Animal Care and Use Committee of Kumamoto University and UNITECK and the Animal Care Committee of Niigata University of Pharmacy and Applied Life Sciences.
Cell Culture
Primary type 1 and type 2 MG were harvested from primary mixed glial cell cultures prepared from neonatal Wistar rat pups as previously reported (Sawada et al., 1990; Shimizu et al., 2008; Suzumura et al., 1987) . Type 1 MG were stimulated with Escherichia coli lipopolysaccharide (LPS; 0.1 mg ml 21 ; serotype 0127:B8; SigmaAldrich) for 24 hr, and type 2 MG were stimulated with rat IL-4 (5 ng ml 21 ; PeproTech EC) for 96 hr. These MG were stored at 2808C until use. Primary rat neurons, astrocytes, and neuroepithelial cells were prepared and cultured as described previously (Nakashima et al., 1999; Tajiri et al., 2004) . Primary rat peritoneal Mu and thioglycolate-elicited Mu were obtained as described previously (Woo et al., 1990) . The murine MG cell lines Ra2, 6-3, and MG5 were maintained as described previously (Kanzawa et al., 2000; Ohsawa et al., 1997) . Monkey kidney COS-7 cells and human HEK293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Rat primary type 1 MG was treated with rat recombinant IL-12 (10 ng ml 21 ; R&D Systems).
Establishment of Mouse Hybridoma Clones
Female BALB/c mice (6 weeks old, n 5 8) were immunized with an intraperitoneal injection of four kinds of rat primary MG (type 1 MG, LPS-stimulated type 1 MG, type 2 MG, or IL-4-stimulated type 2 MG) (1 310 7 cells/mouse, two mice per group) emulsified in an equal volume of Freund's complete adjuvant. After 3 weeks, the immunization was repeated five times at 2-week intervals with the cells (5 310 6 cells/mouse per immunization) in Freund's incomplete adjuvant. Three days after the final injection, the spleens were removed and splenocytes were fused with P3U1 myeloma cells by using polyethylene glycol 1500 (Roche Molecular Biochemicals) according to an established procedure (Koehler and Milstein, 1975) . Hybridoma cells corresponding to supernatants that had positive reactions to lysates of rat MG and negative reactions to lysates of rat Mu were cloned by using the limiting dilution procedure. One monoclonal antibody identified in this study was designated 9F5 and was determined to be IgG1 by using IgFast, the Mouse Monoclonal Antibody Isotyping Kit (BioCytex). The 9F5 was purified from ascites by precipitation with 40% saturated ammonium sulfate and separation via protein A-Sepharose column chromatography (GE Healthcare UK). For some experiments, 9F5 antibody was biotinylated via EZ-Link Sulfo-NHS-LC-biotin (Pierce Biotechnology) according to the manufacturer's recommendations.
Immunoblot Analysis
Immunoblot analysis was performed as described previously (Kawahara et al., 2009) . The blotted membraneswere incubated with one of the following antibodies: 9F5 (1 mg ml 21 ), ED1 (1 mg ml 21 ;
MCA341GA; Serotec), rabbit anti-Iba1 (1 mg ml
21
;019-19741; Wako), goat anti-GPNMB (1 mg ml 21 ;AF2330; R&D Systems), rabbit anti-furin (1:500; PA1-062; Affinity BioReagents), goat anti-CD40 (1:100; T-20; Santa CruzBiotechnology), goat anti-CD86 (1:500; 421340; Genezyme Techne), or mouse anti-b-actin (1:2,000; AC15; Sigma-Aldrich) antibodies.
To determine the amount of N-linked glycosylation, the cell lysate from rat type 1 MG was first denatured in 1% sodium dodecyl sulfate (SDS) (5 min, 608C). Deglycosylation was then performed with 60 U ml 21 peptide-N-glycosidase F (PNGase F;Boehringer Mannheim) in phosphate buffer [0.2M Na 2 HPO 4 -NaOH (pH 7.5) containing 10 mM EDTA, 0.5% NonidetP-40, and protease inhibitors] for 24 hr at 378C (SDS concentration during the PNGase F incubation: 0.05%). O-Glycan chains were analyzed via digestion with a-2,3,6,8,9-neuraminidase (sialidase; Calbiochem) and endo-a-N-acetylgalactosaminidase (O-glycosidase; Calbiochem), according to the manufacturer's instructions. Removal of sugar chains was analyzed by using SDS-PAGE and immunoblotting as described above.
Immunocytochemical Analysis
Mixed glial cells prepared from neonatal Wistar rat brains (P1) were plated on eight-well Lab-Tek chamber slides (Nalge Nunc International) and cultured for 10 days. Rat type 1 MG, type 2 MG, and peritoneal Mu were plated on the chamber slides and cultured for 1 day. The cells were then incubated with 9F5 (1 mg ml 21 ; mouse IgG1), rabbit anti-Iba1 (2.5 mg ml 21 ; Wako), or the isotype matched controls. Alexa Fluor 488-or 594-labeled second antibody (1:500; Molecular Probes) was used. For double-staining with 9F5 and anti-lysosomal-associated membrane protein-1 (LAMP-1; 1 mg ml 21 ; Ly1C6, mouse IgG1;Stressgen Bioreagents), the Zenon labeling kit (Molecular Probes) was used. Stained cells were observed with a confocal laser scanning microscope (Fluoview, Olympus).
Plasmids and Transfection
The rat Gpnmb cDNA clone was isolated via RT-PCR with total RNA from rat type 1 MG. PCR was carried out with rat Gpnmb primers corresponding to nucleotides 53-1860 (GenBank, accession no. BC061725). The product obtained was inserted into pGEM-T easy vector (Promega Corp.) to yield pGEM-T-rGpnmb. To construct pcDNA3.1-Gpnmb, Gpnmb cDNA was released by EcoRI digestion and then subcloned into the EcoRI site of pcDNA3.1 (1; Invitrogen). Expression plasmids for rat a1-PDX, a variant of a1-antitrypsin (AVPM 352 /RVPR 352 ), and murine furin were used (Tsuji et al., 2002) . The a1-PDX cDNA and furin cDNA were subcloned into the BamHI/EcoRI sites and into the HindIII/XbaI sites of pcDNA3.1(1), respectively. Small interfering RNA (siRNA) targeting for human furin (21 oligonucleotides; Pesu et al., 2006) was obtained from Sigma-Aldrich. COS-7 cells were transfected with plasmids via Effectene Transfection Reagent (QIAGEN) according to the manufacturer's protocol. HEK293 cells were cotransfected with plasmids and siRNA by using TransMessenger Transfection Reagent (QIAGEN). As a negative control, the same amount of insert-less plasmid was transfected. For the immunostaining assay, at 72 hr after transfection, cells were fixed in 4% paraformaldehyde in PBS for 10 min and treated with PBS containing 0.05% Triton X-100. Cells were then incubated with 9F5 (1 mg ml 21 ) and goat anti-GPNMB antibody (AF2330, 1 mg ml
21
) and then with Alexa Fluor488-or 594-labeled antibodies against mouse or goat immunoglobulins (1:500; Molecular Probes).
Fluorescence intensities were quantified as described previously (Kawahara et al., 2012) . After photomicrographs were imported into the Scion Image system (NIH), they were quantified via NIH ImageJ software (National Institutes of Health; http://rsb.info.nih. gov/nih-image/). A manually set threshold intensity was kept constant, and the number of pixels in 9F5-and anti-GPNMB antibodyimmunostained cells in an area measuring 400 3 400 mm 2 was determined. At least three areas were quantified per one transfection. The total data for three or four experiments were expressed as means 6 SEM.
RNA Blot Analysis
The total RNA from cells and rat brain were prepared by using the Isogen reagent (Nippon Gene) according to the manufacturer's recommendations. After electrophoresis through formaldehydecontaining agarose gels, RNAs were transferred to nylon membranes. Digoxigenin-labeled antisense RNA probes were synthesized, via a transcription kit (Roche Molecular Biochemicals), from rat Gpnmb cDNA at nucleotide positions 1208-1860 (GenBank, accession no. BC061725) and rat Glyceraldehyde-3-phosphate dehydrogenase cDNA at nucleotide positions 239-1042 (GenBank, accession no. M17701). Hybridization, washing, and chemiluminescent detection of the membranes were performed as recommended by Roche Diagnostics. Filters were analyzed with LAS-1000 Plus (Fuji Photo Film).
Immunoprecipitation and Amino Acid Sequence Analysis
Antibodies were bound to Protein G-Sepharose The extravidin-biotin peroxidase technique was used for some sections tovisualize the label. Endogen peroxidase activity was eliminated from these sections by incubating them with 0.3% hydrogen peroxide in methanol for 15 min. The sections were incubated at room temperature for 1 hr in 5% normal goat serum in PBS and then reacted with 9F5 (1 mg ml 21 ), ED1 (2.5 mg ml 21 ), OX6 (5 mg ml 21 ; MCA46GA; Serotec), or anti-Iba1 (2.5 mg ml 21 ) at room temperature for 2 hr. After excess antibody was washed out with PBS, the sections were incubated with the corresponding biotinylated secondary antibody (1:200, Chemicon International) for 1 hr. The sections were incubated with extravidin-peroxidase complex (Vector Laboratories) at room temperature for 30 min. The presence of peroxidase was revealed by incubation with a diaminobenzidine solution withnickel enhancement or with a diaminobenzidine solution. Finally, sections were coverslipped with NEW MX (Matsunami Glass Industries).
Statistical Analysis
All data were expressed as means6 SEM. For comparisons of three or more groups, we applied Dunnett's multiple comparison test after one-way ANOVA. All statistical analyses including a two-way ANOVA with the Bonferroni post hoc test were performed with GraphPad Prism (GraphPad Software). Significance was defined as P values of <0.05.
Results
Characterization of Monoclonal Antibody 9F5 By Western Blotting: Its Selective Reactivity With Type 1 MG We separated types 1 and 2 MG from a rat mixed glial cell culture using a described method (Sawada et al., 1990; Shimizu et al., 2008; Suzumura et al., 1987) . We confirmed that the expression levels of CD40 and CD86 were higher in type 1 MG than those in type 2 MG (Fig. 1C,D) , as previously reported (Kanzawa et al., 2000 Figure 1Aa showed that 9F5 reacted with 50-to 70-kDa polypeptides of type 1 MG under DTT (2) conditions. Under DTT (1) conditions, 9F5 showed no reaction, indicating that 9F5 recognized a nonreduced epitope of antigen in type 1 MG. In contrast, the antibody against Iba1 reacted with types 1 and 2 MG in a similar fashion (Fig.  1Ab ). After LPS stimulation of type 1 MG, anti-Iba1-reactive proteins were increased, whereas 9F5-reactive proteins were unchanged. This result suggests that expression of antigen molecules for 9F5 and anti-Iba1, was differentially regulated in type 1 MG. Figure 1B shows comparative results of WB analyses with 9F5 and ED1 (another antibody recognizing Mu/MG) in MG, Mu, neurons, and astrocytes under DTT (2) conditions. ED1 reacted with peritoneal Mu and thioglycolate-elicited Mu as expected and reacted similarly with types 1 and 2 MG. In contrast, 9F5 reacted differently: most strongly with type 1 MG, faintly with type 2 MG, and barely with thioglycolate-elicited Mu. The 9F5 reactivity with type 2 MG, although faintly, will be described in Discussion. The 9F5 did not react with peritoneal Mu, neurons, and astrocytes. These results indicate that 9F5 reactivity is highly selective for type 1 MG. Neither 9F5 nor ED1 reacted with mouse MG cell lines, such as 6-3 and Ra2, as expected, because both antibodies were obtained from immunized mice.
Immunocytochemical Reactivity of 9F5 With Different MG Preparations and Peritoneal Mu
To evaluate immunocytochemical reactivity of 9F5, we first tested 9F5 with mixed cell preparations including MG and astrocytes. As Fig. 2Aa shows, 9F5 stained the cells. However, double-immunostaining with 9F5 and anti-Iba1 revealed that 9F5 reacted with Iba11 cells, but the number of 9F51 cells was lower than that of Iba11 cells (Fig. 2Ac) . To clarify which MG type in the mixed cells was responsible for 9F5 staining, we evaluated rat primary types 1 and 2 MG, which were separated from the mixed cells (Fig. 2B ). For this analysis, astrocytes were excluded because all 9F51 cells were included as part of the anti-Iba1-positive cells (anti-Iba1 being an MG marker) (Fig. 2Ac) . Peritoneal Mu were used as another control. Rat primary type 1 MG, type 2 MG, or peritoneal Mu were evaluated by double-staining with 9F5 and anti-Iba1. The 9F5 strongly reacted with type 1 MG (Fig. 2Ba) . Type 2 MG and peritoneal Mu, however, showed very weak reactivity with 9F5 (Fig. 2Be,i) . In contrast, antiIba1 strongly reacted with all MG/Mu populations (Fig.  2Bb ,f,j). Only type 1 MG were double-positive for 9F5 and anti-Iba1 (Fig. 2Bc ). In addition, 9F5 immunoreactivity colocalized with the lysosomal protein Lamp-1 ( Fig. 2C ), which suggests that the antigen molecule for 9F5 is localized in lysosomes. 9F5 1 Iba11 MG (type 1) had a rounder and more amoeboid shape (Fig. 2Bc ) compared with 9F5-Iba1 1 MG (type 2), which had a more ramified form (Fig. 2Bg) . Although 9F5 reacted more weakly with type 2 MG in immunoblot analysis (Fig. 1Ba) , we observed that 9F51 cells in the type 2 cultured cells showed round and amoeboid shape of MG cells ( Fig. 2Be-g ), suggesting the possibility that cultured type 2 cell preparations were contaminated with a little of 9F51 type 1 MG. To confirm this, we further stained the cells with antibody against CD40, a marker for type 1 MG (Kanzawa et al., 2000) , and observed that CD401 cells were expressed in a round and amoeboid shape of MG in mouse mixed glial cell culture (Supporting Information Fig. 3B ). We examined the CD401 cells in mouse mixed glial cell culture, because anti-rat CD40 antibody for immunocytochemistry was not commercially available. These data indicate that 9F5 is selective for a round and amoeboid shape of MG (type 1) in vitro, and will be a useful tool for MG research.
Identification of Rat GPNMB Starting at Lys-170 as the Antigen Protein for 9F5
To identify this antigen protein, samples immunoprecipitated with 9F5 were subjected to SDS-PAGE, and major bands with estimated mol wt 50-70 kDa were analyzed by using an Nterminal amino acid sequencer (Fig. 3) . Edman sequencing of the bands revealed an amino acid sequence of KWNFVYVFHTLGQYFQKLGRXSARVS (Fig. 3C) , which corresponds to Lys-170 to Ser-195 of rat GPNMB/osteoactivin. To confirm that the GPNMB fragments are the antigen for 9F5, we constructed cDNA for rat Gpnmb and expressed it in COS-7 cells. An immunocytochemical analysis revealed that the 9F5 antibody reacted with the pcDNA3.1-Gpnmb-transfected cells and that all 9F51 cells overlapped with cells positive for the anti-GPNMB polyclonal antibody (AF2330; R&D Systems; Fig. 4A ). In a WB analysis using anti-GPNMB antibody, expression of rat GPNMB with mol wt 125 and 95 kDa was observed in transfected cells (Fig. 4B) . In addition, an immunoprecipitation-WB analysis with 9F5 and anti-GPNMB antibody, respectively, revealed that the band with estimated mol wt 50-70 kDa was detected in pcDNA3.1-Gpnmb-transfected cells (Fig. 4C, lane 1) . Comparative WB analysis showed that anti-GPNMB antibody reacted with the mol wt 50-to 70-kDa fragments of GPNMB, in addition to its intact forms with mol wt 95 and 125 kDa in type 1 MG (Fig. 4D) . Furthermore, polypeptides of mol wt 50-70 kDa in type 1 MG were immunoprecipitated by means of anti-GPNMB antibody and detected by WB analysis with 9F5 (Fig. 4E ). All these results indicate that antigen molecule for 9F5 consists of the 50-to 70-kDa fragments of rat GPNMB and that the N-terminal amino acid is Next, to analyze the expression of Gpnmb mRNA and GPNMB protein in MG, Mu, and neuronal cells, we performed Northern and WB analyses (Fig. 5) . We found one transcript of 2.3 kb in type 1 MG, but the high expression level of Gpnmb mRNA was not restricted to type 1 MG (Fig.  5A, lanes 1, 2) , in that we also detected it in type 2 MG (Fig. 5A, lanes 3, 4) and Mu (Fig. 5A, lanes 5, 6, 7) . Gpnmb mRNA was barely detected in the adult rat brain (Fig. 5A , lane 9) and rat C6 glioma cells (Fig. 5B, lane 10) . Figure 5B shows comparative results of WB analyses with 9F5 and anti-GPNMB antibody in MG, Mu, neurons, and astrocytes under DTT (-) conditions. The 9F5 reacted most strongly with type 1 MG, to a much less degree with type 2 MG, and barely with Mu ( Fig. 5Ba ; see also Fig. 1Ba ). In contrast, anti-GPNMB antibody reacted with not only type 1 MG but also type 2 MG and Mu, and it reacted most strongly with murine type 1 cell line 6-3 (Fig. 5Bb) . 9F5 did not react with mouse MG cell lines, including 6-3 and Ra2, because 9F5 antibody was obtained from immunized mice. These results indicate that 9F5 is highly selective for rat type 1 MG and that the 50-to 70-kDa fragments of GPNMB comprise a unique protein that is selectively expressed in type 1 MG.
9F5 Recognizes GPNMB Fragments Generated by Furin-like Protease(s) To characterize the epitope structure of 9F5 more precisely, we analyzed the mechanism of generation of the antigen molecule for 9F5 in type 1 MG. We first investigated the effect of GPNMB glycosylation on 9F5 immunoreactivity, because GPNMB is a highly glycosylated protein (Shikano et al., 2001 ) and the glycosylated form may differ among MG subtypes. Treatment with deglycosidases including PNGase F and sialidase/O-glycosidase (Fig. 6) did not reduce 9F5 immunoreactivity to rat type 1 MG, which suggests that rat GPNMB glycosylation is not the epitope structure of 9F5. 9F5 did not react with the full-length GPNMB protein of 125 and 95 kDa, because removal of N-glycosides from GPNMB in rat type 1 MG showed that (1) the full-length GPNMB (119.6 and 94.9 kDa) shifted to 68.3 and 79.8 kDa, respectively;(2) major two bands detected by 9F5 (64.6 and 51.7 kDa) shifted to 58.7 and 46.5 kDa, respectively; and (3) a minor band detected by 9F5 (137.1 kDa; Figs. 1Ba, 3A, and 5Ba) shifted to 112.1 kDa after the treatment (Fig. 6Aa) . These data indicate that the 137.1 kDa band is not the full-length GPNMB but may be the dimer (S-S-linked or dimerized via sugar chains) of the 64.6-and 51.7-kDa bands.
We next investigated whether 9F5 could recognize GPNMB fragments processed by furin-like protease(s) because premelanosomal protein 17 (Pmel 17), which belongs to the Pmel family including GPNMB, is processed by proprotein convertase/furin (Berson et al., 2003) , and rat GPNMB has a consensus sequence of a furin cleavage site around Lys 170 : His-Gly-Arg-Lys 169 #-Lys 170 (the consensus sequence is underlined; Fig. 3Cb ). Overexpression of furin cDNA significantly increased the fluorescence intensity of 9F5 in pcDNA-Gpnmb-transfected COS-7 cells (F (3, 8) 5 5.506; n 53 wells per group; P < 0.05; Fig. 7) , whereas the fluorescence intensity of anti-GPNMB antibody remained unchanged after cotransfection. Also, cotransfection of cDNA for a1-PDX (an inhibitor of proprotein convertases including furin, PACE4, and PC5) significantly reduced the fluorescence intensity of 9F5 in pcDNA-Gpnmb-transfected COS-7 cells (F (3, 10) 5 11.17; n 5 3-4 wells per group; P < 0.01; Fig.  8 ), whereas the intensity of anti-GPNMB antibody remained unchanged after cotransfection. Moreover, furin siRNA significantly reduced the fluorescence intensity of 9F5 in pcDNAGpnmb-transfected HEK293 cells (F (3, 10) 5 9.895; n 53-4 wells per group; P < 0.01; Fig. 9 ), whereas the intensity of anti-GPNMB antibody remained unchanged after cotransfection. These results suggest that furin-dependent proteolysis of GPNMB, which leads to production of the antigen molecule for 9F5, occurred in these cells. Given that furin is a direct target gene for the IL-12/ STAT4 pathway in Th1 cells (Oksanen et al., 2014; Pesu et al., 2006) , we treated type 1 MG with recombinant IL-12. The cytokine increased both furin protein and antigen for 9F5 of rat type 1 MG with similar kinetics (Fig. 10) . These results suggest that 9F5 immunoreactivity to GPNMB depended on the activity of furin-like protease(s).
Antigen Molecule for 9F5 Is Selectively Expressed in a Subpopulation of MG in Developing Rat Brain
Because 9F5 was selective for type 1 MG in vitro (Figs. 1 and 2), we investigated whether 9F5 would react with MG in developing rat brain. When sagittal sections of postnatal day 5 (P5) brain were stained with 9F5 antibody (Fig. 11) , a number of 9F51 cells occurred in the periphery of several brain regions including lateral ventricles (LV), corpus callosum (CC), pontine nuclei, and fourth ventricles. However, the cortex was essentially negative for 9F51 cells. The 9F51 cells had round and/or amoeboid shapes, as seen in the in vitro cultures (Figs. 2Ba-c and 11 ).
In the tested LV region, 9F51 cells in coronal sections of P5 rat brain were further evaluated by double-staining with anti-Iba1, anti-NG2, anti-nestin, or anti-GFAP antibody, which are antibodies specific for MG, oligodendrocyte precursor cells, neuronal progenitors, and astrocytes, respectively. As Fig. 12a-c shows, 9F51 cells were included in the Iba11 cell population. In contrast, 9F51 cells were not stained with antibodies for NG2 (Fig. 12d-f ) , nestin ( Fig. 12g-i) , or GFAP (Fig. 12j-l) . In addition, 9F5 barely cross-reacted with peripheral Mu in adult rat spleen and liver (Supporting FIGURE 6: Immunoreactivity of 9F5 was not affected by deglycosylation of rat GPNMB protein. A: Extracts of rat type 1 MG were treated with or without N-glycosidase F (PNGase F) overnight at 378C, and they were then subjected to immunoblotting with 9F5 (a), anti-GPNMB (b), or ED1 (c) antibodies. As reported previously for murine dendritic cells (Shikano et al., 2001) , full-length GPNMB (119.6 and 94.9 kDa) in type 1 MG shifted to 68.3 and 79.8 kDa after PNGase F treatment (Ab). B: Extracts of type 1 MG were treated with or without sialidase and O-glycosidase overnight at 378C, and they were then subjected to immunoblotting with 9F5 (a), anti-GPNMB (b), or ED1 (c) antibodies. Immunoreactivity of ED1, an antibody that reacts with sialic acid on rat CD68, disappeared after sialidase treatment (Bc).
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Information Fig. 4) . These results demonstrated that 9F5 selectively immunostained MG among brain cells.
Different Populations of 9F51 MG and Iba11 MG in Rat Brains during P1-P28
We then investigated changes in the expression and distribution of 9F51 MG and compared them with those of Iba11 MG around the supraventricular CC region (Fig. 13) , in which 9F51 MG were most frequently observed (Fig. 11 ). This area is also known as the region for fountains of MG, where amoeboid MG migrate into the brain parenchyma and mature into ramified MG (Hirasawa et al., 2005) . At P1, 9F51 cells had already existed in CC regions (Fig. 11) . At P1-P7, majority of the 9F51 signals was The results shown in A were quantified and are given as means 6 SEM (n 5 3). Fluorescence intensities (9F5 and anti-GPNMB) in cells transfected with pcDNA3.1-Gpnmb/pcDNA3.1were set at 100%. *P < 0.05 by Dunnett's multiple comparison test. C: Cell lysates were also subjected to immunoblot analysis for GPNMB, furin, and b-actin. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] observed in Iba11 cells (Fig. 13A) . 9F51 but Iba1-negative or weakly positive cells [9F5 1 Iba1(2/1)]were occasionally observed (Fig. 13A) . Therefore, we counted and showed the 9F5 and Iba1 double positive cells(9F5 1 Iba11) as the 9F51 MG in Fig. 13B . The 9F51 MG increased during P7-P10 and then decreased markedly at P14 (Fig. 13A,B) . The time course of expression level of Gpnmb mRNA in developing rat brain was consistent with the intensity of the 9F51 signal (Fig. 13C) . Most of the 9F51 signals during P7-P10 were detected in round and amoeboid cells, whereas 9F5-Iba11 MG showed a ramified morphology. Iba11 cells, however, were present in the P1 brain, and they The results shown in A were quantified and are given as means 6 SEM (n 5 3-4). Fluorescence intensities (9F5 and anti-GPNMB) in cells transfected with pcDNA3.1-Gpnmb/pcDNA3.1 were set at 100%. **P < 0.01 by Dunnett's multiple comparison test. C: Cell lysates were also subjected to immunoblot analysis for furin and b-actin. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
were restricted to a subpopulation of MG (9F5 1 Iba11 amoeboid cells) at P7-P10 in developing rat brain and that they may play a major role in CC regions during the period.
Expression of 9F51 Cells in Rat Brains at E10 and E14
To determine the timing in development when 9F51 cells appeared, cryostat sections of E10 and E14 brains were double-stained with 9F5 and anti-Iba1 (Figs. 14 and 15 ). In the E10 rat neural tube, Iba1 1 9F5-cells were present (Fig.  14, region a) . Although 9F5 1 Iba11 cells did not occur in the E10 neural tube, double-positive cells were present outside the brain at this stage (Fig. 14, region b) . In contrast, 9F5 1 Iba11 cells appeared in the E14 rat brain parenchyma (Fig. 15) . This result suggests that 9F51 cells may infiltrate the brain after E10. In addition, cells of 9F5 1 Iba12 or 9F5 1 Iba1(2/1), were observed in E14 rat brain (Fig. 15 , regions a and b).
Expression of 9F51 Cells in E14 Rat Brain and Eyes
At mouse stages E10-E18, Gpnmb mRNA was specifically expressed in retinal pigment epithelium (RPE) (B€ achner et al., 2002) . In agreement with this result, high positive 9F5 staining was found in E14 rat retinal cells, which were obviously Iba1-negative (arrows in Fig. 16a-f ) . The 9F5 1 Iba11 MG-like cells were also observed both outside and inside the retina (some are indicated by arrowheads in Fig. 16a,d ).
Higher magnification photomicrographs (Fig. 16d-f ) showed that 9F5 immunoreactivity was somewhat localized in the RPE, possibly on cytoplasmic and punctate structures such as the melanosome (arrow in Fig. 16d ). Anti-laminin antibody staining revealed that the laminin-positive choroid was the layer outside the 9F51 cell layer (Fig. 16g-i) . Furthermore, 9F5 staining was merged with anti-MITF (microphthalmiaassociated transcription factor) antibody, a marker of RPE cells (Fig. 16j-l) . These results demonstrated that, in the developing rat eye, the antigen for 9F5 was localized both in RPE cells and in a subpopulation of "retinal Iba11 MG."
Discussion
Increasing numbers of studies report that MG are heterogeneous populations and that subtypes or subsets may exist and play different roles in the CNS. However, the lineages and functions of these subtypes remain largely unknown because of the lack of suitable tools to differentiate such heterogeneous MG populations. The present study describes our generation of a novel monoclonal antibody, 9F5, to help remedy this lack.
Truncated GPNMB as the Antigen Molecule for 9F5
We identified rat truncated GPNMB starting at Lys 170 as the antigen molecule for 9F5 (Figs. 3 and 4) . GPNMB, a heavily glycosylated type I transmembrane protein, was expressed in several cells including osteoblasts, melanocytes, and tumor cells (Anderson et al., 2002; Safadi et al., 2001; Weterman et al., 1995) . Shikano et al. (2001) showed that GPNMB was expressed at high levels on dendritic cells but lower levels on Mu. 9F5 strongly reacted with RPECs in E14 rat eye (Fig.  16 ). This result agrees with the report that Gpnmb mRNA was expressed in mouse RPECs at E10-E18 (B€ achner et al., 2002) . The 9F51 cells also colocalized with cells stained with a polyclonal anti-GPNMB antibody in E10 rat eye (data not shown), which confirmed a part of GPNMB as the antigen protein for 9F5. Here, we determined the epitope structure of 9F5. Types 1 and 2 MG, and peritoneal Mu as well, expressed the mRNA and the full-length protein for rat GPNMB, whereas 9F5 reactivity was selective for type 1 MG (Fig. 5) . Although 9F5 reacted with the 50-to 70-kDa fragments, whose Nterminal amino acid is Lys 170 (Fig. 3) , it did not react with the full-length GPNMB protein of 125 and 95 kDa (Fig. 6) .
No alternative splicing form of Gpnmb mRNA occurred in rat type 1 MG (Figs. 3A and 14C) . Deglycosylation by the treatments with PNGase F and sialidase/O-glycosidase (Fig.  6 ), did not reduce 9F5 reactivity with rat type 1 MG. These results suggest that 9F5 reactivity with the GPNMB fragments depends on cleavage between Lys 169 and Lys
170
. We then showed that 9F5 immunoreactivity to the GPNMB fragments (50-70 kDa) depended on furin-like proteaseactivity (Figs. 7-10) . Overexpression of furin cDNA increased expression of the antigen for 9F5 (Fig. 7) , whereas inhibiting furin with a1-PDX or siRNA abrogated this FIGURE 10: IL-12 increases both furin and 9F5 antigen of rat type 1 MG with similar kinetics. Rat type 1 MG were treated with rat recombinant IL-12 (10 ng ml 21 ) at the indicated hours, and cell lysates were subjected to immunoblot analysis for 9F5 antigen, furin, GPNMB, and b-actin.
reactivity (Figs. 8 and 9 ). IL-12, which induces furin mRNA (Pesu et al., 2006) , also increased expression of antigens for furin and 9F5 in rat type 1 MG, with similar kinetics (Fig.  10) . Thus, furin-like protease cleaves the dibasic motif (Lys 169 -Lys 170 ) of GPNMB in type 1 MG, and the 9F5 antigen produced may be a useful marker of furin activity in MG. Additional studies are needed to inspect whether furin activity is higher (or an endogenous furin inhibitor such as serpin is lower) in type 1 MG than that in type 2 MG and peritoneal Mu. The signals of truncated GPNMB disappeared almost completely by treating with furin siRNA (Fig. 9A) , despite furin protein was still abundant (Fig. 9C) . Because furin siRNA and Gpnmb cDNA are mainly co-introduced into the same cells by TransMessenger reagent (Qiagen), furindependent processing must be inhibited in the same cells, resulting in disappearance of the signals of truncated GPNMB in the cells. On the other hand, the transfection efficiency is not 100% in this method. Therefore, it is considered that the furin expression is not knockdown in the cell, into which the plasmid-siRNA complex was not introduced, resulting that furin protein was still abundant. Furochi et al. (2007) been determined. Melanosome-specific protein PMEL 17, with a relatively conserved sequence to GPNMB (Theos et al., 2005) , undergoes proteolytic cleavage by a furin-like convertase to form active PMEL 17 in pigment cells (Berson et al., 2003) , which suggests that a furin-like protease forms the GPNMB fragments in RPECs (Fig. 16 ).
Physiological Significance of Truncated GPNMB in Developing Brain
The three-dimensional structure of rat GPNMB has not yet been resolved. However, Lys 170 is believed to locateat the protein surface, given the furin-like protease processing at the dibasic motif (Lys 169 -Lys 170 ). Infection of neonatal rat glial cells with Toxoplasma gondii caused a marked 136-fold increase in Lys 170 acetylation of rat GPNMB (Bouchut et al., 2015) . Mice and humans infected with T. gondii increased the furin activity of T cells in an IL-12-dependent manner and augmented host resistance against parasites via secretion of cytokines including interferon-c (Oksanen et al., 2014) . The 9F51 cells localized in specific areas of neonatal rat brain including the forebrain subventricular zone, CC, and retina (areas affected by toxoplasmosis in neonatal human brain). Lys 170 acetylation in toxoplasmosis may disrupt the interaction between furin and GPNMB, because, the amino acid substitution with a hydrophobic aliphatic side chain at the P 1 ' position (i.e., Lys 170 ) is not suitable as a furin substrate (Nakayama, 1997; Tian, 2009) . Because many cytokines are dysregulated in Gpnmb mutant mice (Abdelmagid et al., 2014; Wilson et al., 2015) , future studies are required to reveal the role of GPNMB and its Lys acetylation for furin activity required for cytokine maturation in 9F51 MG. Distribution of 9F51 MG in Neonatal Rat Brain Given its high selectivity for type 1 MG, 9F5 may be applied to monitor changes in distribution and morphology of 9F51 MG in neonatal rat brain. The 9F51 MG comprised a fraction of Iba11 total MG during P1-P28 stages of brain development, which confirms that MG subtype(s), at least 9F51 and 9F52, exist in vivo. Also, 9F51 MG were round and/or amoeboid in brain areas including the subventricular zone and CC regions (Figs. 11 and 12) . In neo-and postnatal brains, the 9F51 cell number peaked at P10 in the parenchyma around the CC near the LV, decreased rapidly at P14, and was lower by P21 (Fig.  13) . Rat neuronal progenitor cells begin to proliferate at E13, start to migrate before birth, and begin to differentiate into neurons just after birth (Ferrer et al., 1990; Spreafico et al., 1995) . Simultaneously with or after differentiation, neuronal apoptosis occurs; apoptosis peaks during P5-P7 and completes by P14 (Ferrer et al., 1990; Spreafico et al., 1995) . In our study here, changes in 9F51 cell numbers during development showed a similar pattern, although the peak (P7-P10) came slightly later than the reported period of neuronal apoptosis. MG functionin axon guidance and clearance of apoptotic neurons (Hamilton and Rome, 1994; Miller and Kaplan, 2001) . Therefore, 9F51 MG in developing rat brain may be involved in migration and differentiation of neuronal progenitor cells and in clearance of dying neurons.
Microglial insulin-like growth factor-1 (IGF-1) is reportedly required for survival of layer V corticospinal motor neurons in the developing brain (Ueno et al., 2013) . However, how IGF-11 MG accumulate around subcortical white matter during development remained unknown. The distribution pattern of IGF-11 MG seemed similar to that of our 9F51 MG in developing rat brain, and furin was required for pro-IGF-1 processing. Amoeboid MG express IGF-1 in developing rat brain (Kaur et al., 2006) , which suggests that IGF-11 MG may be 9F51 MG. Because GPNMB is involved in the pathophysiological process in motor neuron diseases (e.g., amyotrophic lateral sclerosis) (Tanaka et al., 2012) , future investigations must determine how 9F51 MG contribute to motor neuron survival.
One fate-mapping study revealed that adult MG derive from yolk-sac Mu (Ginhoux et al., 2010) . Monocytes from aorta-gonad-mesonephros, fetal liver, or bone marrow may also infiltrate the brain, especially the meninges, choroid plexus, and perivascular spaces (Andjelkovic et al., 1998; Prinz and Priller, 2014; Sheng et al., 2015) . Although MG from yolk-sac Mu contribute to adult brain function, bone marrow-derived myeloid cells/monocytes of peripheral origin may also contribute to brain pathology including Alzheimer's disease, especially around Ab plaque Savage et al., 2015) .
In the E10 rat neural tube, Iba1 1 9F52 cells, but not 9F51 cells, were observed; 9F5 1 Iba11 cells occurred only outside the neural tube (Fig. 14) . At E14, however, 9F5 1 Iba11 cells appeared in brain parenchymal regions, such as amygdala (Fig. 15, regions c and d) . These results indicate that Iba1 1 9F52 cells, which had invaded brain parenchyma earlier than 9F51 cells, were already present at E10, whereas 9F5 1 Iba11 cells remained outside the parenchyma until later. In E14 rat brain parenchyma, we observed three different cells, namely 9F5 1 Iba12, 9F5 1 Iba1(2/ 1), and 9F5 1 Iba11 cells (Fig. 15) . The 9F5 1 Iba12 cells were also observed in some parts of P1-P7 rat brain (Fig.  13A) . The 9F5 1 Iba1(2/1) cells are thought to be immature MG that will differentiate into MG. The 9F5-Iba11 cells in E10 brain parenchyma are believed to be resident MG derived from yolk-sac Mu. Therefore, 9F5-Iba11 cells, possibly type 2 MG, may be derived from yolk-sac Mu. However, present data do not give conclusion about this MG subtype. Future studies must characterize this subpopulation.
In our study, we detected 9F5 immunoreactivity in RPECs of E10-E14 rat eye (Fig. 16 , data not shown), and in retinal MG subpopulations in E14 rat eye (Fig. 16d-f ). This finding is a sharp contrast to anti-Iba1 antibody, which did not stain RPECs. RPECs originate from the neural tube (Martinez-Morales et al., 2004) . Therefore, present results suggest that 9F51 MG may be of neuroectodermal origin. However, both RPECs and 9F51 MG express the same antigen for 9F5, whereas the neuroepithelial progenitor cells do not (Fig. 1Ba, lane 12) . RPECs help to maintain retinal function. Brain 9F51 MG and retinal RPECs may possess similar phagocytic functions that are possible to result from the common antigen for 9F5.
In this study, we did not perform lineage tracking of 9F5-immunoreactive myeloid cells in the CNS. Antigen molecule for 9F5 is expressed in developing rat brain, but the molecule was almost disappeared in adult rat brain (Fig.  13B) . Because the P7 and P10 rat brains contained many kinds of proliferating cells (Imamoto and Leblond, 1978) , it is impossible to label specifically 9F5-positive cells by BrdU method. This problem may be overcome by the genetic fate mapping studies. However, this technology requires the generation of many mouse lines: a tamoxifen-sensitive GpnmbCreERT2 mouse line followed by crossbreeding to reporter lines. Therefore, lineage-tracking study is beyond the scope of this manuscript, but it is an important question to be solved in near future.
Lastly, we generated Gpnmb-GFP knock-in mice (Supporting Information Figs. 1-3) to investigate the functional relevance of GPNMB for microglia in vivo. GFP was expressed in a subpopulation of Iba11 MG in mixed glial cell culture from P3 neonatal brain of heterozygous Gpnmb-GFP knock-in mice and in the white matter regions including CC of P5-P7 neonatal brains, but not in liver (Supporting Information Figs. 2 and 3) . Homozygous Gpnmb-KO mice did not show any growth retardation including body weight loss in neonatal development (Supporting Information Fig.  1F ). However, 23% of homozygous Gpnmb-KO mice (3 of 13 mice) and 8% of the heterozygous mice (1 of 12 mice) exhibited spontaneous seizure phenotype at age of 10-to 26.5-month old (Supporting Information Table 1 , Supporting Information Videos 1 and 2). The results were consistent with the characteristics of DBA/2J mice with dysfunctional GPNMB expression: DBA/2J mice are susceptible to seizureinducing model (Ferraro et al., 1999) . Collectively, GPNMB may play some roles to prevent age-related epilepsy in rodent, but more definitive data is required in the future study.
It remains unknown whether 9F51 MG in developing rat brain is phenotypically equivalent to that of CD401 type 1 MG in vitro. Definitive evidence is lacking, mainly due to two reasons: (i) commercial unavailability of anti-rat CD40 antibody for immunohistochemistry, and (ii) unavailability of lineage analysis tools including a tamoxifen-sensitive GpnmbCreERT2 mouse line. Comprehensive characterization of the 9F51 MG in vivo including lineage analysis should be solved in near future.
In summary, we developed the new monoclonal antibody 9F5 that showed no cross-reactivity with peritoneal Mu and recognized a fraction of Iba11 MG-round and/or amoeboid type 1 MG in vitro. We demonstrated the existence of 9F51 MG in vivo at an early developmental stage of rat brains and eyes. Because the antigen molecule for 9F5 was identified as the GPNMB fragments processed by furin-like protease(s), 9F5 may be useful for elucidating new roles of 9F51 MG during rat brain development, and in possible relations with neuroinflammation and neurodegenerative diseases.
